12.01.2021 Geratherm Medical AG  DE0005495626

DGAP-News: Geratherm Medical AG: Geratherm subsidiary LMT Medical receives approval for Incubator System nomag(R) in China


DGAP-News: Geratherm Medical AG / Key word(s): Regulatory Approval
Geratherm Medical AG: Geratherm subsidiary LMT Medical receives approval for Incubator System nomag(R) in China

12.01.2021 / 14:32
The issuer is solely responsible for the content of this announcement.

DGAP-News: Geratherm subsidiary LMT Medical receives approval for Incubator System nomag(R) in China

Geratherm Medical AG/LMT Medical (ISIN: DE 0005495626): LMT Medical, a subsidiary of Geratherm Medical AG, has received product approval for the Chinese market for its MRI-capable incubator system for newborns.

The basis for the approval, which was granted over a period of five years, was, among other things, a successful clinical study conducted in China. With the LMT product, incubator system nomag(R) IC, premature and newborn infants can be examined directly in MRI - Magnetic Resonance Tomography - to diagnose any possible brain or organ damage. This is currently a unique solution worldwide. To date, more than 100 LMT Medical systems are in use worldwide. The Chinese market is considered one of the largest future markets for these systems. The approval will already have a positive impact on the company's sales development in 2021.

Geratherm Medical AG

Investor Relations

Geratherm Medical AG
Firmensitz: Fahrenheitstraße 1, 99331 Geratal
Registergericht: Amtsgericht Jena, HRB 111272
Vorstand: Dr. Gert Frank; Dipl.-Kfm. Christian Frick
Aufsichtsratsvorsitzender: Dipl.-Kfm. Rudolf Bröcker
Tel. 036205/98 0
E-Mail: [email protected]

Short company profil:
Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services and MRI Diagnostic Incubator Systems for premature babies and newborns. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Healthcare Index.

Dr. Gert Frank

12.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: Geratherm Medical AG
Fahrenheitstraße 1
99331 Geratal
Phone: +49 (0)36205 98-0
Fax: +49 (0)36205 98-1 15
E-mail: [email protected]
Internet: www.geratherm.com
ISIN: DE0005495626
WKN: 549562
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1160113

End of News DGAP News Service

1160113  12.01.2021 


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022
Umsatzerlöse1 21,41 21,03 21,52 19,85 27,47 23,94 25,85
EBITDA1,2 3,71 1,77 2,80 2,35 4,35 2,31 3,55
EBITDA-Marge3 17,33 8,42 13,01 11,84 15,84 9,65 13,73
EBIT1,4 2,54 0,63 1,99 1,05 3,04 0,59 2,07
EBIT-Marge5 11,86 3,00 9,25 5,29 11,07 2,46 8,01
Jahresüberschuss1 2,25 0,22 0,83 0,29 1,90 0,33 1,08
Netto-Marge6 10,51 1,05 3,86 1,46 6,92 1,38 4,18
Cashflow1,7 0,79 2,47 1,35 1,54 3,92 0,92 2,79
Ergebnis je Aktie8 0,45 0,14 0,23 0,11 0,41 0,02 0,19
Dividende8 0,50 0,47 0,40 0,25 0,40 0,12 0,15
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

Geratherm Medical
WKN Kurs in € Einschätzung Börsenwert in Mio. €
549562 5,500 Halten 29,95
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
16,67 26,86 0,71 23,51
1,40 10,75 1,16 7,99
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
0,15 0,15 2,73 28.08.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 25.08.2023 - 29.06.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-6,84% -19,79% 10,22% -4,51%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Geratherm Medical AG  ISIN: DE0005495626 können Sie bei EQS abrufen

Medtech , 549562 , GME , XETR:GME